{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:19:04Z","timestamp":1793121544771,"version":"4.5.0"},"reference-count":147,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21721003"],"award-info":[{"award-number":["21721003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2016YFA0203200"],"award-info":[{"award-number":["2016YFA0203200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2013YQ170585"],"award-info":[{"award-number":["2013YQ170585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["YJKYYQ20180038"],"award-info":[{"award-number":["YJKYYQ20180038"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20220204094YY"],"award-info":[{"award-number":["20220204094YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["20210204029YY"],"award-info":[{"award-number":["20210204029YY"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Technology of China","award":["21721003"],"award-info":[{"award-number":["21721003"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["2016YFA0203200"],"award-info":[{"award-number":["2016YFA0203200"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["2013YQ170585"],"award-info":[{"award-number":["2013YQ170585"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["YJKYYQ20180038"],"award-info":[{"award-number":["YJKYYQ20180038"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["20220204094YY"],"award-info":[{"award-number":["20220204094YY"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Science and Technology of China","award":["20210204029YY"],"award-info":[{"award-number":["20210204029YY"]}],"id":[{"id":"https:\/\/ror.org\/02kv4zf79","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["21721003"],"award-info":[{"award-number":["21721003"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["2016YFA0203200"],"award-info":[{"award-number":["2016YFA0203200"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["2013YQ170585"],"award-info":[{"award-number":["2013YQ170585"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["YJKYYQ20180038"],"award-info":[{"award-number":["YJKYYQ20180038"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["20220204094YY"],"award-info":[{"award-number":["20220204094YY"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Instrument Developing Project of the Chinese Academy of Sciences","award":["20210204029YY"],"award-info":[{"award-number":["20210204029YY"]}],"id":[{"id":"https:\/\/ror.org\/034t30j35","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["21721003"],"award-info":[{"award-number":["21721003"]}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["2016YFA0203200"],"award-info":[{"award-number":["2016YFA0203200"]}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["2013YQ170585"],"award-info":[{"award-number":["2013YQ170585"]}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["YJKYYQ20180038"],"award-info":[{"award-number":["YJKYYQ20180038"]}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["20220204094YY"],"award-info":[{"award-number":["20220204094YY"]}]},{"name":"Science and Technology Development Plan of Jilin Province","award":["20210204029YY"],"award-info":[{"award-number":["20210204029YY"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease that affects approximately one-quarter of the global adult population, posing a significant threat to human health with wide-ranging social and economic implications. The main characteristic of NAFLD is considered that the excessive fat is accumulated and deposited in hepatocytes without excess alcohol intake or some other pathological causes. NAFLD is a progressive disease, ranging from steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Therefore, NAFLD will probably emerge as the leading cause of end-stage liver disease in the coming decades. Unlike other highly prevalent diseases, NAFLD has received little attention from the global public health community. Liver biopsy is currently considered the gold standard for the diagnosis and staging of NAFLD because of the absence of noninvasive and specific biomarkers. Due to the complex pathophysiological mechanisms of NAFLD and the heterogeneity of the disease phenotype, no specific pharmacological therapies have been approved for NAFLD at present, although several drugs are in advanced stages of development. This review summarizes the current evidence on the pathogenesis, diagnosis and treatment of NAFLD.<\/jats:p>","DOI":"10.3390\/ijms24032844","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T02:21:12Z","timestamp":1675304472000},"page":"2844","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"24","author":[{"given":"Xunzhe","family":"Yin","sequence":"first","affiliation":[{"name":"State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1770-3998","authenticated-orcid":false,"given":"Zuojia","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Physics, Stony Brook University, Stony Brook, New York, NY 11794-3400, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009\u20132019","volume":"75","author":"Golabi","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: A consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., and Ramnarain, D. (2022). Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Dis., 22.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic Landscape for NAFLD in 2020","volume":"158","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: A multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","article-title":"Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Del. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","article-title":"Insulin Resistance, Obesity and Lipotoxicity","volume":"Volume 960","author":"Yazici","year":"2017","journal-title":"Obesity and Lipotoxicity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What\u2019s in a name? Renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.14739","article-title":"The NAFLD-MAFLD debate: Eminence vs evidence","volume":"41","author":"Fouad","year":"2021","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1038\/s41467-021-25674-5","article-title":"Deficiency of intestinal Bmal1 prevents obesity induced by high-fat feeding","volume":"12","author":"Yu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1055\/s-0028-1091985","article-title":"Role of Fatty Acids in the Pathogenesis of Obesity and Fatty Liver: Impact of Bariatric Surgery","volume":"28","author":"Verna","year":"2008","journal-title":"Semin. Liver Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1262-3636(08)74599-3","article-title":"The role of the lipogenic pathway in the development of hepatic steatosis","volume":"34","author":"Postic","year":"2008","journal-title":"Diabetes Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4254\/wjh.v5.i10.550","article-title":"Lipotoxicity in the liver","volume":"5","author":"Zambo","year":"2013","journal-title":"World J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-02998-x","article-title":"The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases","volume":"38","author":"Eguchi","year":"2021","journal-title":"Pharm. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF03194597","article-title":"The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism","volume":"47","author":"Chmurzynska","year":"2006","journal-title":"J. Appl. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"836058","DOI":"10.3389\/fonc.2022.836058","article-title":"Acetyl-CoA Carboxylases and Diseases","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s13105-011-0110-6","article-title":"Role of lipid droplet proteins in liver steatosis","volume":"67","author":"Okumura","year":"2011","journal-title":"J. Physiol. Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI95802","article-title":"Hippo-mediated suppression of IRS2\/AKT signaling prevents hepatic steatosis and liver cancer","volume":"128","author":"Jeong","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1097-2765(05)00010-9","article-title":"Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob\/ob mice","volume":"6","author":"Shimomura","year":"2000","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","article-title":"Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis","volume":"51","author":"Argo","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1007\/s12072-017-9808-z","article-title":"New concepts on the clinical course and stratification of compensated and decompensated cirrhosis","volume":"12","author":"Morabito","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_37","first-page":"221","article-title":"Molecular pathways in non-alcoholic fatty liver disease","volume":"7","author":"Berlanga","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-319-48382-5_19","article-title":"Non-Alcoholic Fatty Liver Disease","volume":"960","author":"Engin","year":"2017","journal-title":"Obes. Lipotoxic."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T., and Kadowaki, T. (2021). Role of Insulin Resistance in MAFLD. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084156"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1073\/pnas.1103451108","article-title":"Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2","volume":"108","author":"Jornayvaz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22678","DOI":"10.1074\/jbc.M704213200","article-title":"Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance","volume":"282","author":"Choi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1194\/jlr.M052977","article-title":"Hepatic insulin resistance in ob\/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation","volume":"56","author":"Sajan","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellsig.2017.12.005","article-title":"Coordinated regulation of hepatic FoxO1, PGC-1 alpha and SREBP-1c facilitates insulin action and resistance","volume":"43","author":"Sajan","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.01.003","article-title":"Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis","volume":"52","author":"Akazawa","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Leveille, M., and Estall, J.L. (2019). Mitochondrial Dysfunction in the Transition from NASH to HCC. Metabolites, 9.","DOI":"10.3390\/metabo9100233"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1002\/1878-0261.12818","article-title":"The FABP12\/PPAR gamma pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells","volume":"14","author":"Liu","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/978-3-319-55330-6_25","article-title":"Insulin Resistance and Mitochondrial Dysfunction","volume":"Volume 982","author":"Patti","year":"2017","journal-title":"Mitochondrial Dynamics in Cardiovascular Medicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17075","DOI":"10.1073\/pnas.0707060104","article-title":"Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27141","DOI":"10.1074\/jbc.M704391200","article-title":"Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis","volume":"282","author":"Barreyro","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3748\/wjg.v21.i10.2875","article-title":"Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors","volume":"21","author":"Camps","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5170402","DOI":"10.1155\/2016\/5170402","article-title":"Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells","volume":"2016","author":"Magee","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.21070","article-title":"Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression","volume":"43","author":"Ikura","year":"2006","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/nm.4334","article-title":"Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4","volume":"23","author":"Zhao","year":"2017","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat. Rev. Immun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","article-title":"The menage a trois of autophagy, lipid droplets and liver disease","volume":"18","author":"Hunter","year":"2022","journal-title":"Autophagy"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Harjumaki, R., Pridgeon, C.S., and Ingelman-Sundberg, M. (2021). CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158221"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/liv.12741","article-title":"The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob\/ob mice through suppression of mitochondrial ROS\/RNS and inflammation","volume":"35","author":"Chung","year":"2015","journal-title":"Liver Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1053\/j.gastro.2017.10.012","article-title":"Mitochondrial Dysfunction, Through Impaired Autophagy, Leads to Endoplasmic Reticulum Stress, Deregulated Lipid Metabolism, and Pancreatitis in Animal Models","volume":"154","author":"Biczo","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., and Tiribelli, C. (2006). The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 6.","DOI":"10.1186\/1471-230X-6-33"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kahn, H.S. (2005). The \u201clipid accumulation product\u201d performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. BMC Cardiovasc. Disord., 5.","DOI":"10.1186\/1471-2261-5-26"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12986-017-0206-2","article-title":"Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults","volume":"14","author":"Dai","year":"2017","journal-title":"Nutr. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejogrb.2017.05.014","article-title":"The predictive effect of inflammatory markers and lipid accumulation product index on clinical symptoms associated with polycystic ovary syndrome in nonobese adolescents and younger aged women","volume":"214","author":"Tola","year":"2017","journal-title":"Eur. J. Obstet. Gyn. Reprod. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3345\/kjp.2019.00248","article-title":"Lipid accumulation product is a predictor of nonalcoholic fatty liver disease in childhood obesity","volume":"62","author":"Ozcabi","year":"2019","journal-title":"Korean J. Pediatr."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bedogni, G., Kahn, H.S., Bellentani, S., and Tiribelli, C. (2010). A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol., 10.","DOI":"10.1186\/1471-230X-10-98"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Jung, T.Y., Kim, M.S., Hong, H.P., Kang, K.A., and Jun, D.W. (2020). Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092851"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Foschi, F.G., Conti, F., Domenicali, M., Giacomoni, P., Borghi, A., Bevilacqua, V., Napoli, L., Berardinelli, D., Altini, M., and Cucchetti, A. (2021). External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030520"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"a009712","DOI":"10.1101\/cshperspect.a009712","article-title":"The Thrombospondins","volume":"3","author":"Adams","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2337\/dc21-0131","article-title":"Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes","volume":"44","author":"Lee","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/liv.14776","article-title":"Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD","volume":"41","author":"Kimura","year":"2021","journal-title":"Liver Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/hep.31995","article-title":"Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis","volume":"74","author":"Kozumi","year":"2021","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1194\/jlr.M007096","article-title":"Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"51","author":"Feldstein","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.3748\/wjg.v22.i44.9844","article-title":"Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population","volume":"22","author":"Liu","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","article-title":"Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogenesis","volume":"64","author":"Pirola","year":"2015","journal-title":"Gut"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic Accuracy and Reliability of Ultrasonography for the Detection of Fatty Liver: A Meta-Analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1111\/j.1572-0241.2007.01526.x","article-title":"The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation","volume":"102","author":"Hamaguchi","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of Laboratory Tests, Ultrasound, or Magnetic Resonance Elastography to Detect Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.04.003","article-title":"Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic\/histological parameters in various liver diseases","volume":"72","author":"Ballestri","year":"2017","journal-title":"Metabolism"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jum.15154","article-title":"Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis from Nonalcoholic Steatohepatitis: Validity in the Average Obese Population","volume":"39","author":"Nelson","year":"2020","journal-title":"J. Ultrasound Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymgme.2021.01.007","article-title":"US-FLI score\u2014Is it possible to predict the steatosis grade with an ultrasonographic score?","volume":"132","author":"Xavier","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jum.15693","article-title":"Liver Fat Assessment in Multiview Sonography Using Transfer Learning with Convolutional Neural Networks","volume":"41","author":"Byra","year":"2022","journal-title":"J. Ultrasound Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1148\/radiol.2020191160","article-title":"Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks","volume":"295","author":"Han","year":"2020","journal-title":"Radiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ultrasmedbio.2022.05.031","article-title":"Comparative Study of Raw Ultrasound Data Representations in Deep Learning to Classify Hepatic Steatosis","volume":"48","author":"Sanabria","year":"2022","journal-title":"Ultrasound Med. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/postgradmedj-2018-136316","article-title":"Diagnosis and management of non-alcoholic fatty liver disease","volume":"95","author":"Jennison","year":"2019","journal-title":"Postgrad. Med. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2010.01.008","article-title":"Non-invasive assessment of hepatic steatosis: Prospective comparison of the accuracy of imaging examinations","volume":"52","author":"Lee","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/acem.14174","article-title":"Hepatic Steatosis: An Incidental Finding That Deserves Attention","volume":"28","author":"Kontrick","year":"2021","journal-title":"Acad. Emerg. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (cap): A novel vcte (tm) guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients with Nonalcoholic Fatty Liver Disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: An individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017Part 1: Definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Piazzolla, V.A., and Mangia, A. (2020). Noninvasive Diagnosis of NAFLD and NASH. Cells, 9.","DOI":"10.3390\/cells9041005"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/hep.31121","article-title":"Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH","volume":"72","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"344","DOI":"10.14366\/usg.21150","article-title":"Noninvasive assessment of hepatic steatosis using a pathologic reference standard: Comparison of CT, MRI, and US-based techniques","volume":"41","author":"Bae","year":"2022","journal-title":"Ultrasonography"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/dme.14356","article-title":"Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes","volume":"37","author":"Hydes","year":"2020","journal-title":"Diabet. Med."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Zhang, C., and Yang, M. (2021). Current Options and Future Directions for NAFLD and NASH Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147571"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Marchesini","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00125-021-05628-8","article-title":"Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: A randomised controlled trial","volume":"65","author":"Thomsen","year":"2022","journal-title":"Diabetologia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1042\/CS20150308","article-title":"Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: A randomized controlled trial","volume":"129","author":"Hallsworth","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20150447","article-title":"Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease","volume":"130","author":"Cuthbertson","year":"2016","journal-title":"Clin. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/clinem\/dgab795","article-title":"The Effect of High-intensity Interval Training vs Moderate-intensity Continuous Training on Liver Fat: A Systematic Review and Meta-Analysis","volume":"107","author":"Sabag","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/13543784.2020.1704731","article-title":"Trends in pioglitazone use among US adults with type 2 diabetes and suspected nonalcoholic fatty liver disease","volume":"29","author":"Le","year":"2020","journal-title":"Expert Opin. Investig. Drug."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30418","article-title":"Improvements in Histologic Features and Diagnosis Associated with Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results from the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/hep4.1680","article-title":"Relationship of ELF and PIIINP with Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial","volume":"5","author":"Gawrieh","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/apt.15216","article-title":"Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: A post-hoc analysis of the PIVENS trial","volume":"49","author":"Corey","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"615409","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD Patients with Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes: A Randomized Controlled Trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41467-020-20303-z","article-title":"Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH","volume":"12","author":"Dong","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jgh.15131","article-title":"Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis","volume":"36","author":"Gurka","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","article-title":"Treatment options for alcoholic and non-alcoholic fatty liver disease: A review","volume":"23","author":"Singh","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes the STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"Birkenfeld","year":"2018","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0566","article-title":"Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dom.13650","article-title":"A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"Brown","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR alpha Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-018-3525-0","article-title":"Long-Term Outcomes After Bariatric Surgery: A Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding","volume":"29","author":"Hindle","year":"2019","journal-title":"Obes. Surg."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of Bariatric Surgery with Cancer Risk and Mortality in Adults with Obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/bjs\/znab245","article-title":"Perioperative mortality in bariatric surgery: Meta-analysis","volume":"108","author":"Robertson","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and Risks of Bariatric Surgery in Adults A Review","volume":"324","author":"Arterburn","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11695-018-3539-7","article-title":"Bariatric\/Metabolic Surgery in the Asia-Pacific Region: APMBSS 2018 Survey","volume":"29","author":"Ohta","year":"2019","journal-title":"Obes. Surg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/dom.14304","article-title":"Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis","volume":"23","author":"Panunzi","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ecl.2020.02.003","article-title":"Common and Rare Complications of Bariatric Surgery","volume":"49","author":"Shah","year":"2020","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.4254\/wjh.v7.i28.2819","article-title":"Treating morbid obesity in cirrhosis: A quest of holy grail","volume":"7","author":"Kumar","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s11695-017-2925-x","article-title":"Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series","volume":"28","author":"Eilenberg","year":"2018","journal-title":"Obes. Surg."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00535-020-01686-8","article-title":"Confounding factors of non-invasive tests for nonalcoholic fatty liver disease","volume":"55","author":"Wai","year":"2020","journal-title":"J. Gastroenterol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2844\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:21:44Z","timestamp":1760120504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/3\/2844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":147,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24032844"],"URL":"https:\/\/doi.org\/10.3390\/ijms24032844","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}